Leerink Partners Maintains a Buy Rating on Quanterix (QTRX)
Leerink Partners analyst Puneet Souda maintained a Buy rating on Quanterix (QTRX) on June 7. The company’s shares closed last Wednesday at $61.98.
According to TipRanks.com, Souda is a 5-star analyst with an average return of 18.3% and a 59.9% success rate. Souda covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, AbCellera Biologics, and Castle Biosciences.
Quanterix has an analyst consensus of Moderate Buy, with a price target consensus of $78.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $92.57 and a one-year low of $24.22. Currently, Quanterix has an average volume of 374.2K.
Based on the recent corporate insider activity of 110 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QTRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Quanterix Corp. is a life sciences company, which develops ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its Single Molecule Array (Simoa) technology platform uses single molecule measurements to access previously undetectable proteins. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Lexington, MA.